-------------------- It is better to be thought a fool than to speak and remove all doubt. Posts: 357 | From: Minnesota | Registered: Jun 2005
| IP: Logged |
posted
GRANT LIFE SCIENCES INC Quick Quote: GLIF 0.03 (+0.01) Grant Life Sciences Chairman Featured in Exclusive Interview With WallSt.net 7/7/2006 NEW YORK, July 7, 2006 /PRNewswire via COMTEX News Network/ --
On July 5, Stan Yakatan, Chairman of Grant Life Sciences, Inc. (OTC Bulletin Board: GLIF) updated the investment community in an exclusive interview with www.wallst.net . Topics covered in the interview include an overview of the Company and the markets it serves, recent press releases, current capitalization, upcoming strategic and financial milestones.
To hear the interview in its entirety, visit www.wallst.net , and click on "Interviews." Interviews require free registration, and can be accessed either by locating the respective company's ticker symbol under the appropriate exchange on the left-hand column of the "Interviews" section of the site, or by entering the respective company's ticker symbol in the Search Archive window.
About Grant Life Sciences, Inc.
Grant Life Sciences, Inc. develops products to improve the efficiency of detecting and diagnosing cervical cancer, including a sensitive, reliable, non-invasive, point-of-care test. The diagnostic assay being developed by the Company has shown promise in detecting cervical cancer and its precursors, a disease that kills in excess of 300,000 women annually. According to the CDC there are currently more than 120 million cervical screening tests administered annually in the U.S. and Europe. In developed nations more than 120 million eligible women, 20 years old and above, still do not get Pap smears, and globally more than 1.7 billion over the age of 20 have never been checked due to cultural, religious or economic reasons. Further information is available at: www.grantlifesciences.com .
About WallSt.net
www.wallst.net is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. The website is a leading provider of financial news, media, tools and community-driven applications for investors. www.wallst.net offers visitors free membership to its in-depth executive interviews, exclusive editorial content, breaking news, and several proprietary applications. In addition to its website, WallStreet Direct organizes investor conferences, publishes a newspaper, and provides multimedia advertising solutions to small and mid-sized publicly traded companies. We are expecting to receive one hundred seventy five dollars from Grant Life Sciences, Inc. for the dissemination of this press release. For a complete list of our advertisers, and advertising relationships, visit http://www.wallst.net/disclaimer/disclaimer.asp
Nick Iyer of Digital Wall Street, Inc., +1-800-4-WALL-ST http://www.prnewswire.com Copyright (C) 2006 PR Newswire. All rights reserved.
Posts: 330 | From: oregon | Registered: Dec 2004
| IP: Logged |
posted
still uptrending. i thought i got in late at .025... guess not!!! :-) if we end HOD today, could be a nice green gap in the morn. watch out for P&D!!! cover your arse.
-------------------- Cashing checks in two forms: Money and Reality
GLTA, The Phat Man Posts: 1236 | Registered: Apr 2006
| IP: Logged |
-------------------- It is better to be thought a fool than to speak and remove all doubt. Posts: 357 | From: Minnesota | Registered: Jun 2005
| IP: Logged |
90010 _________________________________ (Address of principal executive offices)
___________ (Zip Code)
Registrant’s telephone number, including area code:
(801) 261-8736
Copies to: Gregory Sichenzia, Esq. Yoel Goldfeder, Esq. Sichenzia Ross Friedman Ference LLP 1065 Avenue of the Americas New York, New York 10018 Phone: (212) 930-9700 Fax: (212) 930-9725
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
At the 2006 Annual Meeting of Stockholders of Grant Life Sciences, Inc. (the “Company”) the stockholders of the Company, by an affirmative vote of 64% of its outstanding shares of common stock, agreed to the filing of a Certificate of Amendment to the Articles of Incorporation of the Company pursuant to which the Company’s authorized shares of common stock would be increased from 150,000,000 shares to 750,000,000 shares. In accordance with the foregoing, on June 1, 2006 the Company filed a Certificate of Amendment to its Articles of Incorporation with the Secretary of State of the State of Nevada, which became effective on June 2, 2006.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits
Exhibit Number
Description 3.6
Certificate of Amendment to the Articles of Incorporation of Grant Life Sciences, Inc.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Grant Life Sciences, Inc.
Date: June 7, 2006 By: /s/ Don Rutherford Name: Don Rutherford Title: Chief Financial Officer
Posts: 330 | From: oregon | Registered: Dec 2004
| IP: Logged |
posted
considering this report is from over a month ago regarding the increase in OS, is it not possible that those shares have been mostly absorbed? by the looks of the volume since the release you provided above, it looks like they have not. however, the recent interview on wallst.net, while certainly providing fuel to this play's recent fire, may have been what the company was anticipating regarding major volume increases and buying pressure. either way, this is a super volatile play. have my finger on the trigger with this one for tomorrow. would love to see another HUGE jump like today, but wouldn't bet the farm on it either. glty and thanks for the DD
-------------------- Cashing checks in two forms: Money and Reality
GLTA, The Phat Man Posts: 1236 | Registered: Apr 2006
| IP: Logged |
Grant Life Sciences Extends Through September 2006 Its Memorandum of Understanding (MOU) With Diagnostic Technology Ltd
LOS ANGELES, CA -- (MARKET WIRE) -- 07/11/06 -- MOU, Announced in April 2006, Includes Payment of $250,000 to Grant Upon Successful Completion of DTL's Due Diligence and Signing of a Licensing Agreement, Plus Ongoing Royalties Upon Commercialization of the Resulting Product; Also, DTL Would Conduct and Fund All Development Costs, Including Clinical Trials, Associated With the Commercialization of the Products Developed From Grant's Cervical Cancer Diagnostic Technology
"This Event Positions Grant Life Sciences to Begin the Execution of Its New Corporate Strategy: (1) Acquire New Products and Technologies Through In-Licensing Activities; (2) Optimize These Products and Technologies; and Then (3) Out-License Them for Further Development and Sales, or (4) Drive Sales Through Our Established Marketing Channels." Dr. Hun-Chi Lin, President and Chief Scientist
Grant Life Sciences Inc. (OTCBB: GLIF) announced today it has extended through Sept. 2006 its Memo of Understanding (MOU) with Israel-based Diagnostic Technology Ltd. (DTL) related to Grant's cervical cancer-diagnostic technology (U.S. Patent No. 6,743,593). Under the MOU, Grant will receive an upfront payment of $250,000 upon successful completion of DTL's due diligence and the subsequent signing of a Licensing Agreement. Under the Licensing Agreement, DTL would assume all costs and efforts associated with commercialization of products, including clinical trials, developed by DTL from Grant's cervical cancer-diagnostic technology platform. Upon commercialization, DTL would pay Grant an ongoing royalty on sales of the products developed, according to the MOU.
Assuming acceptable due diligence by DTL, the definitive Licensing Agreement is expected to be signed by September 2006. Upon signing, DTL will immediately assume all of the costs associated with turning Grant's core technology related to cervical-cancer diagnostics into a commercially viable product. The diagnostic product based on Grant's technology is expected to augment and complement DTL's established suite of diagnostics aimed at the women's health market.
"This relationship, once fully consummated, will represent a very significant milestone in the evolution of our company into a commercial entity," said Hun-Chi Lin, Ph.D., Grant's President and Chief Scientist. "Grant will finally have the opportunity to focus its efforts on boosting revenues from sales in India and Southeast Asia of its extensive portfolio of rapid AccuDx tests for Malaria, Dengue Fever, HIV-1, HIV-2, and numerous other diseases. In addition, the market for cervical cancer testing is substantial, and DTL intends to aggressively conclude development of Grant's novel, protein-based diagnostic test and commercialize the product expeditiously."
"We are happy with the opportunity ... to fast-forward development and commercialization of a diagnostic product based on Grant's cervical cancer diagnosis technology," said Hamutal Meiri, Ph.D., Chief Executive Officer of DTL, in a Grant press release dated April 6, 2006. "We hope that their technology will enable the detection of the presence of antibodies produced only by cancer-causing HPV-types and profile them." (According to the National Cancer Institute there are some 100 types of HPV. However, only about 7 to 15 of these appear to cause cervical cancer, with certain HPV-types especially virulent in this regard. Cancer-causing HPV-types express certain unique proteins that help trigger the disease.) "The parties to the MOU believe that the product developed using Grant's technology can distinguish these cancer-causing proteins from those made by non-cancer-causing HPV-types," added Dr. Meiri "DTL therefore expects that using Grant's technology will enable it to determine whether a woman has cervical cancer or pre-cervical cancer conditions."
"Grant has recently established OEM arrangements to manufacture and distribute more than two-dozen immunoassay tests for the large markets in India and Southeast Asia," said Stan Yakatan, Grant's Chairman. "In addition, Grant plans to continue adding new products in the areas of infectious diseases, hormones, and cancer biomarkers, for sale to these markets in the future."
About Diagnostic Technology Ltd. (DTL)
DTL, based in Haifa, Israel, is a public company that has licensed from Technion a technology for the prediction of the risk of preeclampsia in maternal serum. According to the CDC, preeclampsia affects five to seven percent of all pregnant women and can result in: loss of life; blindness; motor and mental disorders or premature newborns; pregnancy hypertension; and kidney, liver and cardiovascular malfunctioning. It is estimated that nearly $30 billion is spent today in healthcare costs to treat women with preeclampsia and their newborns. DTL's simple blood test for the early prediction of preeclampsia is now in clinical trials. TEUZA, an Israeli venture fund, is the major investor in the Company. On Jan. 31, 2006, PerkinElmer, Inc, announced that it had secured the exclusive global rights to the test for identifying patients at risk for preeclampsia developed by DTL.
About Grant Life Sciences Inc.
Grant Life Sciences Inc. Grant Life Sciences, Inc. (OTCBB: GLIF), a development stage company, engages in the research, development, marketing, and sale of diagnostic kits for the screening, monitoring, and diagnosis of diseases with emphasis on women's health, infectious diseases, and cancers.
Forward-Looking Safe Harbor Statement
With the exception of historical information, the matters discussed in this press release are "forward-looking statements" that involve a number of risks and uncertainties. The actual future results of Grant Life Sciences could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rates and unanticipated events such as terrorist activities, results of clinical trials, and market acceptance of the Company's products. In some cases, "forward-looking statements" can be identified by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," or other comparable terminology. Although Grant Life Sciences believes that the expectations reflected in the "forward-looking" statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such "forward-looking statements" will be achieved. Grant Life Sciences undertakes no duty to update any of the "forward-looking statements," whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such "forward-looking statements." For further risk factors associated with our Company, review our SEC filings.
Contact: Don Rutherford CFO 949-521-1232
Posts: 158 | From: Phila,PA | Registered: Mar 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
